Tempest Therapeutics
TPST
23 hedge funds and large institutions have $20.5M invested in Tempest Therapeutics in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 15 closing their positions.
142% more capital invested
Capital invested by funds: $8.5M → $20.5M (+$12M)
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
23% less funds holding
Funds holding: 30 → 23 (-7)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
59% less call options, than puts
Call options by funds: $229K | Put options by funds: $563K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$11.2M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$5.36M |
| 3 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$3.29M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
+$2.24M |
| 5 |
MS
Maven Securities
St Helier,
Jersey
|
+$1.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$601K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$480K |
| 3 |
Two Sigma Advisers
New York
|
-$298K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$197K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$186K |
TPST Hedge Fund Activity: Q2 2021 in Review
23 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q2 2021, worth a combined $20.5M — up 142% from $8.5M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TPST and 8 opened new positions — a net loss of 7 holders — while 3 trimmed existing stakes and 6 added.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $11.2M. The largest seller was Renaissance Technologies, cutting an estimated $601K.
- 23 institutional investors held Tempest Therapeutics (TPST) as of Q2 2021, down from 30 in Q1 2021.
- Funds reported $20.5M of Tempest Therapeutics stock for Q2 2021, up 142% quarter-over-quarter.
- 8 funds opened new Tempest Therapeutics positions in Q2 2021 and 15 closed out, a net change of -7 holders.
- The largest Tempest Therapeutics buyer in Q2 2021 was Fidelity Investments, an estimated $11.2M added.
- The largest Tempest Therapeutics seller in Q2 2021 was Renaissance Technologies, an estimated $601K sold.
Based on aggregated 13F filings for Q2 2021.